Management and Follow-up of Sporadic Cribriform-Morular Thyroid Carcinoma After the 2022 World Health Organization Reclassification
AACE Endocrinology and Diabetes · 2026-09 · 13 (5) · 679-684
DOI: 10.1016/j.aed.2026.05.001 ↗Kurz gefasst
Fallbericht in der Zeitschrift AACE Endocrinology and Diabetes, 2026-09. Verfasst von Vanessa Cando-Bonilla und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Cribriform-morular thyroid carcinoma (CMTC) has been reclassified as a distinct thyroid tumor entity in the 2022 World Health Organization classification, no longer considered a subtype of papillary thyroid carcinoma. This redefinition raises important questions regarding postoperative management, including the need for radioactive iodine (RAI), thyroid-stimulating hormone (TSH) suppression, thyroglobulin monitoring, and screening for familial adenomatous polyposis (FAP). We report an apparently sporadic case and discuss a risk-adapted management approach. Case Report: A 24-year-old woman presented with a progressively enlarging right-sided neck mass. Thyroid ultrasound revealed a 2.8 cm predominantly solid, hypoechoic nodule (ACR TI-RADS 4), and fine-needle aspiration cytology was classified as Bethesda category V. Total thyroidectomy was performed. Histopathology confirmed CMTC with cribriform and morular architecture and focal vascular invasion, without extrathyroidal extension or nodal involvement (pT2N0). Immunohistochemistry demonstrated nuclear β-catenin expression and absence of thyroglobulin staining. There was no personal or family history of thyroid disease or polyposis. Colonoscopy was normal, and germline whole-exome sequencing did not identify pathogenic variants in adenomatous polyposis coli or other cancer-predisposition genes. Given the absence of high-risk features and no evidence of FAP, RAI therapy and TSH suppression were not administered. The patient remains disease-free after 24 months, under surveillance with periodic cervical ultrasonography.
Discussion
CMTC management should not automatically follow conventional papillary thyroid carcinoma paradigms. In apparently sporadic, low-risk cases, a conservative postoperative strategy may be appropriate.
Conclusion
This case supports an individualized, risk-adapted approach to CMTC, in which omission of RAI and aggressive TSH suppression may be reasonable without compromising oncologic safety.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
- Endocrinology Service, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
- Endocrine Oncology Service, Instituto do Câncer do Estado de São Paulo Octávio Frias de Oliveira, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
- Department of Head and Neck Surgery, Instituto do Câncer do Estado de São Paulo Octávio Frias de Oliveira, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
- Department of Head and Neck Surgery, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
- Laboratório de Carboidratos e Radioimunoensaio (LIM18), Hospital das Clinicas (HCFMUSP) Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
Zitieren
APA
Cando-Bonilla, V., Mercante, A. M. C., Batista, R. L., Cavalheiro, B. G., Hoff, A. O., Kowalski, L. P., & Toyoshima, M. T. K. (2026). Management and Follow-up of Sporadic Cribriform-Morular Thyroid Carcinoma After the 2022 World Health Organization Reclassification. AACE Endocrinology and Diabetes, 13(5), 679-684. https://doi.org/10.1016/j.aed.2026.05.001
Vancouver
Cando-Bonilla V, Mercante AMC, Batista RL, Cavalheiro BG, Hoff AO, Kowalski LP, et al. Management and Follow-up of Sporadic Cribriform-Morular Thyroid Carcinoma After the 2022 World Health Organization Reclassification. AACE Endocrinology and Diabetes. 2026;13(5):679-684. doi:10.1016/j.aed.2026.05.001
BibTeX
@article{CandoBonilla2026,
author = {Cando-Bonilla, Vanessa and Mercante, Ana Maria de Cunha and Batista, Rafael Loch and Cavalheiro, Beatriz Godoi and Hoff, Ana O and Kowalski, Luiz Paulo and Toyoshima, Marcos Tadashi Kakitani},
title = {Management and Follow-up of Sporadic Cribriform-Morular Thyroid Carcinoma After the 2022 World Health Organization Reclassification},
journal = {AACE Endocrinology and Diabetes},
year = {2026},
volume = {13},
number = {5},
pages = {679--684},
doi = {10.1016/j.aed.2026.05.001}
}
EUVIMED